Publikationen in Zusammenarbeit mit Forschern von Hospital Miguel Servet (26)

2024

  1. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 864-871

2023

  1. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA

    Genome Medicine, Vol. 15, Núm. 1

  2. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

    Nature Communications, Vol. 14, Núm. 1

  3. Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours

    European Journal of Cancer, Vol. 188, pp. 39-48

  4. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402

    Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1497-1505

2022

  1. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

2021

  1. Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: A biomarker study from the GEMCAD 1402 trial

    Clinical Cancer Research, Vol. 27, Núm. 10, pp. 2890-2898

  2. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

    Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312

  3. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 988-1000

  4. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus

    Pancreatology, Vol. 21, Núm. 1, pp. 215-223

2020

  1. VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)

    Cancer Medicine, Vol. 9, Núm. 3, pp. 1008-1016

2019

  1. Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy before Standard Chemoradiotherapy and Surgery in Patients with High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial

    JAMA Oncology, Vol. 5, Núm. 11, pp. 1566-1573

  2. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)

    British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544

  3. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

    Oncologist, Vol. 24, Núm. 1, pp. 38-46

  4. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580

  5. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma

    Oncologist, Vol. 24, Núm. 10, pp. 1375-1383

2018

  1. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432

  2. Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours

    Cancer Treatment Reviews, Vol. 70, pp. 209-222

2015

  1. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 972-981

2014

  1. A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond

    Cancer Letters, Vol. 351, Núm. 1, pp. 30-40